Albiorix Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 33.05%
- Profit Growth -26.39%
- Ebitda 38.85%
- Net Worth 13.30%
- Total Assets 71.16%
About Albiorix Pharmaceuticals
Albiorix Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 October 2011 and has a history of 13 years and three months. Its registered office is in 24 Parganas, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sashi Chauhan and Bhanu Chauhan serve as directors at the Company.
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85100WB2011PTC168945
- Company No.
168945
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Oct 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Albiorix Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sashi Chauhan  | Director | 31-Oct-2011 | Current |
| Bhanu Chauhan | Director | 31-Oct-2011 | Current |
Financial Performance of Albiorix Pharmaceuticals.
Albiorix Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 33.05% increase. The company also saw a substantial fall in profitability, with a 26.39% decrease in profit. The company's net worth Soared by an impressive increase of 13.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Albiorix Pharmaceuticals?
In 2019, Albiorix Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Albiorix Pharmaceuticals?
Albiorix Pharmaceuticals has a workforce of 18 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Albiorix Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Albiorix Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.